Weed (BUDZ) Cash from Financing Activities (2010 - 2026)
Weed's (BUDZ) quarterly Cash from Financing Activities came in at $29200.0 in Q1 2026, up 134.64% year-on-year from $12444.7 in Q1 2025, and down 80.84% quarter-over-quarter from $152403.0 in Q4 2025.
Weed (BUDZ) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Weed's Cash from Financing Activities history runs 13 years deep, the most recent figure standing at $29200.0 for Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 134.64% year-over-year to $29200.0 in Q1 2026; TTM through Mar 2026 was $183603.0, a 12.97% decrease from a year earlier, with the FY2025 full-year figure at $70103.0, down 75.43% from the prior year.
- Cash from Financing Activities fell to $29200.0 in Q1 2026 per BUDZ's latest filing, from $152403.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $281344.0 in Q4 2024 and bottomed at -$530000.0 in Q3 2023.
- The 5-year median for Cash from Financing Activities is -$10095.0 (2023), against an average of -$22004.6.
- Across the five-year window, Cash from Financing Activities jumped 1975.63% in 2024 and slumped 743.0% in 2025, its largest moves.
- Year by year, Cash from Financing Activities stood at -$39981.0 in 2022, then surged by 62.48% to -$15000.0 in 2023, then soared by 1975.63% to $281344.0 in 2024, then tumbled by 45.83% to $152403.0 in 2025, then tumbled by 80.84% to $29200.0 in 2026.
- Per Business Quant, the three latest BUDZ Cash from Financing Activities figures stand at $29200.0 (Q1 2026), $152403.0 (Q4 2025), and $2000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Weed | 3.72 Mn | 3.72 Mn | - | 29,200.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29,200.00 |
| Mar 31, 2026 | 29,200.00 |
| Dec 31, 2025 | 152,403.00 |
| Dec 31, 2025 | 152,403.00 |
| Jun 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | -84,300.00 |
| Mar 31, 2025 | -84,300.00 |
| Dec 31, 2024 | 281,344.00 |
| Dec 31, 2024 | 281,344.00 |
| Sep 30, 2024 | 18,925.00 |
| Sep 30, 2024 | 18,925.00 |
| Jun 30, 2024 | -5,000.00 |
| Jun 30, 2024 | -5,000.00 |
| Mar 31, 2024 | -10,000.00 |
| Mar 31, 2024 | -10,000.00 |
| Dec 31, 2023 | -15,000.00 |
| Dec 31, 2023 | -15,000.00 |
| Sep 30, 2023 | -530,000.00 |
| Sep 30, 2023 | -530,000.00 |